Discontinued drugs in 2012 – 2013: hepatitis C virus infection

Bibliography

• WHO. Hepatitis C. 2014. Available from: www.who.int/mediacentre/factsheets/fs164/en/ [Last accessed 2 July 2014]
   Google Scholar
• Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012;26:401-12
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Zappulo E, et al. Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world? Expert Rev Anti Infect Ther 2014;12:763-73
   PubMed Web of Science ®Google Scholar
• Gentile I, Zappulo E, Bonavolta R, et al. Prevalence and titre of antibodies to cytomegalovirus and Epstein-Barr virus in patients with autism spectrum disorder. In Vivo 2014;28:621-6
   PubMed Web of Science ®Google Scholar
• Gentile I, Viola C, Borgia F, et al. Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem 2009;16:1115-21
   PubMed Web of Science ®Google Scholar
• Gentile I, Carleo MA, Borgia F, et al. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus. Expert Opin Investig Drugs 2010;19:151-9
   PubMed Web of Science ®Google Scholar
• Coppola N, Pisaturo M, Tonziello G, et al. Efficacy of Pegylated interferon alpha-2a and alpha-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis. BMC Infect Dis 2012;12:1471-2334
   Web of Science ®Google Scholar
• Coppola N, Pisaturo M, Sagnelli C, et al. Peg-interferon Plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors. PLoS One 2014;9:e94542
   PubMed Web of Science ®Google Scholar
• Morisco F, Granata R, Stroffolini T, et al. Sustained virological response: a milestone in the treatment of chronic hepatitis C. World J Gastroenterol 2013;19:2793-8
   PubMed Web of Science ®Google Scholar
• Gentile I, Borgia G. Surrogate endpoints and non-inferiority trials in chronic viral hepatitis. J Hepatol 2010;52:778
   PubMed Web of Science ®Google Scholar
• Lange CM, Bojunga J, Ramos-Lopez E, et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol 2011;54:887-93
   PubMed Web of Science ®Google Scholar
• Ismail MH. Prediction of sustained virologic responses to combination therapy of pegylated interferon-alpha and ribavirin in patients with chronic hepatitis C infection. J Family Community Med 2013;20:35-40
   PubMedGoogle Scholar
• Borgia G, Gentile I, Fortunato G, et al. Homocysteine levels and sustained virological response to pegylated-interferon alpha2b plus ribavirin therapy for chronic hepatitis C: a prospective study. Liver Int 2009;29:248-52
   PubMed Web of Science ®Google Scholar
• Distante S, Bjoro K, Hellum KB, et al. Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver 2002;22:269-75
   PubMedGoogle Scholar
• Gentile I, Viola C, Paesano L, et al. Iron depletion before HCV antiviral therapy: a pilot, randomized, controlled trial. J Clin Apher 2009;24:190-6
   PubMed Web of Science ®Google Scholar
• Abu-Mouch S, Fireman Z, Jarchovsky J, et al. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients. World J Gastroenterol 2011;17:5184-90
   PubMed Web of Science ®Google Scholar
• Nimer A, Mouch A. Vitamin D improves viral response in hepatitis C genotype 2-3 naive patients. World J Gastroenterol 2012;18:800-5
   PubMed Web of Science ®Google Scholar
• Coppola N, Marrone A, Pisaturo M, et al. Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection. Eur J Clin Microbiol Infect Dis 2014;33:559-67
   PubMed Web of Science ®Google Scholar
• Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433-44
   PubMed Web of Science ®Google Scholar
• Gentile I, Borgia F, Buonomo AR, et al. A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir. Curr Med Chem 2013;20:3733-42
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Hezode C, Zeuzem S, et al. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012;56:S88-S100
   PubMed Web of Science ®Google Scholar
• Gentile I, Borgia F, Coppola N, et al. Daclatasvir: the First of a New Class of Drugs Targeted Against Hepatitis C Virus NS5A. Curr Med Chem 2014;21:1391-404
   PubMed Web of Science ®Google Scholar
• Lange CM, Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 2013;58:583-92
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Borgia F, et al. Ledipasvir : a novel synthetic antiviral for the treatment of HCV infection. Expert Opin Investig Drugs 2014;23:561-71
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Borgia F, et al. MK-5172: a second-generation protease inhibitor for the treatment of hepatitis C virus infection. Expert Opin Investig Drugs 2014;23:719-28
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo A, Zappulo E, et al. Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. Therapeutics and Clinical Risk Management 2014;10:493-504
   PubMed Web of Science ®Google Scholar
• Gentile I, Borgia F, Zappulo E, et al. Efficacy and Safety of Sofosbuvir in Treatment of Chronic Hepatitis C: the Dawn of a New Era. Rev Recent Clin Trials 2014;9:1-7
   PubMedGoogle Scholar
• Gentile I, Coppola N, Buonomo AR, et al. Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Expert Opin Investig Drugs 2014;21:1-13
   Google Scholar
• Gentile I, Buonomo AR, Borgia G. Dasabuvir: a non-nucleoside inhibitor of. NS5B for the treatment of Hepatitis C virus infection. Rev Recent Clin Trials 2014;29:29
   Google Scholar
• BioCryst Pharmaceuticals. Company presentation. 2011. Slide 11 Available from: http://investor.shareholder.com/common/download/download.cfm?companyid=BCRX&fileid=464677&filekey=93e801de-45ab-460e-a1bc-3b09d1061275&filename=BCRX%20Q1%202011%20slides%20final%2004May11.pdf [Last accessed 30 June 2014]
   Google Scholar
• BioCryst Pharmaceuticals. Company pipeline. 2012. Available from: www.biocryst.com/clinical_pipeline [Last accessed 30 June 2014]
   Google Scholar
• BioCryst Pharmaceuticals. Form 8-K. 25 Jan 2013. Available from: www.sec.gov/Archives/edgar/data/882796/000119312513024464/d473944d8k.htm [Last accessed 30 June 2014]
   Google Scholar
• BioCryst Pharmaceuticals. Company presentation. 2012. Slide 25 Available from: http://files.shareholder.com/downloads/BCRX/1701493358x0x543050/48faee1a-2526-42cc-a55b-aa89304fb132/BCRX%20Q4%202011%20slides%2016Feb12%20Final.pdf [Last accessed 30 June 2014]
   Google Scholar
• Shanta B Pravin K, et al. P-1889: preclinical characterization of BCX5191, a highly potent, selective and pan-genotypic nucleoside analog inhibitor of hepatitis C polymerase. In: Pharmaceuticals B. editor. 63rd AASLD; Boston MA: 2012
   Google Scholar
• BioCryst Pharmaceuticals. Press release. 2012. Available from: http://investor.shareholder.com/biocryst/releasedetail.cfm?ReleaseID=648696 [Last accessed 30 June 2014]
   Google Scholar
• Staab TII. Roth capital partners conference presentation, Slide 21. BioCryst Pharmaceuticals. ROTH Capital Growth Stock Conference; 14 Mar 2012; California. Available from: http://files.shareholder.com/downloads/BCRX/1210976025x0x553394/9ca3a3f0-af8b-48df-a94f-edf985c724b8/BCRX%20ROTH%20Capital%20Conf%20In-room%20Presentation%20Final%2014March12.pdf [Last accessed 30 June 2014]
   Google Scholar
• BioCryst Pharmaceuticals. Press release. 2012. Available from: http://investor.shareholder.com/biocryst/ReleaseDetail.cfm?ReleaseID=725543 [Last accessed 30 June 2014]
   Google Scholar
• Stonehouse J. 31st Annual J.P. Morgan Healthcare Conference Presentation, Slide 16. BioCryst Pharmaceuticals. 31st Annual JP Morgan Healthcare Conference;. 10 January 2013; San Francisco. Available from: http://files.shareholder.com/downloads/BCRX/1210976025x0x626823/ab951312-320e-4804-b91f-ebc4b71f5393/BCRX%20JPMorgan%20Conf%20inroom%20FINAL%2010Jan13.pdf [Last accessed 30 June 2014]
   Google Scholar
• Medivir Pharmaceuticals. Company presentation, Slide 16. 2011. Available from: www.medivir.se/v4/images/pdf/2011/EASL_Breakfast_2_April_in_Berlin_WEB_versio.pdf [Last accessed 30 June 2014]
   Google Scholar
• Hartmanis M, Edenius C, Piir R. A collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C, Slide 24. Medivir Pharmaceuticals. 31st Annual JP Morgan Healthcare Conference; San Francisco. 2013. Available from: www.medivir.se/v4/images/pdf/2013/J.P.Morgan-Healthcare-Seminar-2013-WEB.pdf [Last accessed 30 June 2014]
   Google Scholar
• Medivir Pharmaceuticals. Press release. 2013. Available from: www.medivir.se/v5/se/uptodate/pressrelease.cfm?year=2013&releaseid=797651 [Last accessed 30 June 2014]
   Google Scholar
• Medivir Pharmaceuticals. Medivir makes strategic decision to focus proprietary hepatitis C R&D efforts exclusively on nucleotide-based polymerase inhibitors. Wall Street J . Available from: http://online.wsj.com/article/PR-CO-20130815-903829.html [Last accessed 30 June 2014]
   Google Scholar
• Idenix provides update on IDX19368 development program. IDX19368, for which idenix has submitted an IND application, has been placed on clinical hold by FDA. 2012; Idenix Pharmaceuticals. Available from: http://files.shareholder.com/downloads/IDIX/0x0x593673/9045738f-e4fc-4cdf-9f81-2327b156d264/IDIX_News_2012_8_27_General_Releases.pdf [Last accessed 30 June 2014]
   Google Scholar
• Standring D. Building a leading antiviral franchise, Slide 9. In:; Idenix Pharmaceuticals. Stifel Nicolaus Healthcare Conference; 6 September 2012. Available from: http://files.shareholder.com/downloads/IDIX/2014946012x0x597833/50aa478f-88b0-48ad-9725-30a480238fb8/IdenixStifel_Slides_Sept_2012_FINAL_presentation.pdf [Last accessed 30 June 2014]
   Google Scholar
• Renaud R. Building a leading antiviral franchise, Slide 6. Idenix Pharmaceuticals. UBS Global Life Sciences Conference; 19 - 20 September 2012; New York. Available from: http://files.shareholder.com/downloads/IDIX/2014946012x0x600064/3f79656d-257d-47c0-8057-36c39bdfc020/IDENIX_UBS_presentation_FINAL.pdf [Last accessed 30 June 2014]
   Google Scholar
• Idenix Pharmaceuticals. Press release. 2012. Available from: http://ir.idenix.com/releasedetail.cfm?ReleaseID=637761 [Last accessed 30 June 2014]
   Google Scholar
• Idenix Pharmaceuticals. Press release. 2012. Available from: http://ir.idenix.com/releasedetail.cfm?ReleaseID=702442 [Last accessed 30 June 2014]
   Google Scholar
• Standring D. Building a leading antiviral franchise, Slide 9. Idenix Pharmaceuticals. Stifel Nicolaus Healthcare Conference; 6 September 2012. Available from: http://files.shareholder.com/downloads/IDIX/2014946012x0x597833/50aa478f-88b0-48ad-9725-30a480238fb8/IdenixStifel_Slides_Sept_2012_FINAL_presentation.pdf [Last accessed 30 June 2014]
   Google Scholar
• Idenix Pharmaceuticals. Press releases. 2013. Available from: http://ir.idenix.com/releasedetail.cfm?ReleaseID=737733 [Last accessed 30 June 2014]
   Google Scholar
• Ando I, Adachi T, Ogura N, et al. Preclinical characterization of JTK-853, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 2012;56:4250-6
   PubMed Web of Science ®Google Scholar
• Rodriguez-Torres M, Pai S, Gerhardt B, et al. Antiviral activity, safety and pharmacokinetics of JTK-853, a novel non-nucleoside polymerase inhibitor, in a 3-day proof-of-concept study in HCV genotype 1 patients, and evaluation of emergence of resistance. HEP DART 2011. Front Drug Dev Viral Hepatitis 2011;7. abstract 57
   Google Scholar
• Achillion Pharmaceuticals. Press release. 2010. Available from: http://ir.achillion.com/releasedetail.cfm?ReleaseID=490918 [Last accessed 30 June 2014]
   Google Scholar
• Achillion Pharmaceuticals. Form 10-Q. 2012.Page 12. Available from: www.sec.gov/Archives/edgar/data/1070336/000119312512222039/d319644d10q.htm [Last accessed 30 June 2014]
   Google Scholar
• Achillion Pharmaceuticals. Form 10-Q. 2012.Page 13. Available from: www.sec.gov/Archives/edgar/data/1070336/000119312512460561/d398351d10q.htm [Last accessed 30 June 2014]
   Google Scholar
• Achillion Pharmaceuticals. Company presentation. 2011. Available from: www.achillion.com/PL/pdf/ACH2928_EASL_2011.pdf [Last accessed 30 June 2014]
   Google Scholar
• Yongsen Z, Guangwei Y, Fabrycki JL, et al. In vitro combination studies of ACH-1625 (HCV NS3 protease inhibitor) & ACH-2928 (HCV NS5A inhibitor) in presence and absence of ribavirin. Hepatology 2010;52:1214A
   Web of Science ®Google Scholar
• Zhao Y, Yang G, Fabrycki JL, et al. In vitro combination studies Of ACH-1625 (HCV NS3 PROTEASE INHIBITOR) and ACH-2928 (HCV NS5A INHIBITOR) in presence and absence of ribavirin. Hepatology 2010;52:1214A-A
   Web of Science ®Google Scholar
• Huang M, Yang G, Patel D, et al. ACH-2928: a novel highly potent hcv ns5a inhibitor with favorable preclinical characteristics. J Hepatol 2011;54:S479-S79
   Web of Science ®Google Scholar
• Vince B, Lawitz E, Searle S, et al. Novel NS5A inhibitor ACH-2928 Phase 1 results in HCV GT-1 patients. J Hepatol 2012;56:S480-S81
   Web of Science ®Google Scholar
• Achillion Pharmaceuticals. Press release. 2011. Available from: http://ir.achillion.com/releasedetail.cfm?ReleaseID=590298 [Last accessed 30 June 2014]
   Google Scholar
• Achillion Pharmaceuticals. Press release. 2011. Available from: http://ir.achillion.com/releasedetail.cfm?releaseid=629849 [Last accessed 30 June 2014]
   Google Scholar
• Achillion Pharmaceuticals. Form 10-Q. 2012.Page 11. Available from: www.sec.gov/Archives/edgar/data/1070336/000119312512460561/d398351d10q.htm [Last accessed 30 June 2014]
   Google Scholar
• Pawlotsky JM. NS5A inhibitors in the treatment of hepatitis C. J Hepatol 2013;59:375-82
   PubMed Web of Science ®Google Scholar
• Roche Pharmaceuticals. Company pipeline. 2010. Available from: www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm?ta=%25&Phase=%25&submit=Show+pipeline [Last accessed 30 June 2014]
   Google Scholar
• Roche Pharmaceuticals. Company Presentation. Slide 82. 2012. Available from: www.roche.com/irp120201_full.pdf [Last accessed 30 June 2014]
   Google Scholar
• Roche Pharmaceuticals. Company Presentation, Slide 103. 2 Feb 2011. Available from: www.roche.com/irp110202.pdf [Last accessed 30 June 2014]
   Google Scholar
• GlaxoSmithKline Pharmaceuticals. Annual Report. 2010.Page 204. Available from: www.gsk.com/investors/reps10/GSK-Annual-Report-2010.pdf [Last accessed 30 June 2014]
   Google Scholar
• GlaxoSmithKline Pharmaceuticals. ClinicalTrials.gov. Aug 2012. Available from: www.clinicaltrials.gov/show/NCT01332552 [Last accessed 30 June 2014]
   Google Scholar
• Voitenleitner C, Crosby R, Wang A, et al. Preclinical characterization of GSK2485852, a novel hcv polymerase inhibitor. J Hepatol 2011;54:S328-S28
   PubMed Web of Science ®Google Scholar
• Voitenleitner C, Crosby R, Walker J, et al. In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother 2013;57:5216-24
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline Pharmaceuticals. ClinicalTrials.gov. 2011. Available from: http://www.clinicaltrials.gov/show/NCT01332552 [Last accessed 30 June 2014]
   Google Scholar
• Vertex Pharmaceuticals. Press releases. 2011. Available from: http://files.shareholder.com/downloads/VRTX/1289810863x0x475730/2fd04443-3f48-4077-bd41-b4f6d4466b5e/VRTX_News_2011_6_13_Webcasts.pdf [Last accessed 30 June 2014]
   Google Scholar
• Vertex Pharmaceuticals. Press releases. 2012. Available from: http://investors.vrtx.com/releasedetail.cfm?ReleaseID=709250 [Last accessed 30 June 2014]
   Google Scholar
• Vertex and Alios Pharmaceuticals. Press release. 2011. Available from: http://investors.vrtx.com/releasedetail.cfm?ReleaseID=632006 [Last accessed 30 June 2014]
   Google Scholar
• Vertex Pharmaceuticals. Press releases. 2012. Available from: http://investors.vrtx.com/releasedetail.cfm?ReleaseID=696581 [Last accessed 30 June 2014]
   Google Scholar
• Vertex Pharmaceuticals. ClinicalTrials.gov. 2012. Available from: http://clinicaltrials.gov/show/NCT01554085 [Last accessed 30 June 2014]
   Google Scholar
• Merck Pharmaceuticals. ClinicalTrials.gov. 2012 & 2013. Available from: http://www.clinicaltrials.gov/show/NCT01554189 [Last accessed 30 June 2014]
   Google Scholar
• Shi ST, Herlihy KJ, Graham JP, et al. Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 2009;53:2544-52
   PubMed Web of Science ®Google Scholar
• Hammond JL, Rosario MC, Wagner F, et al. Antiviral activity of the HCV polymerase inhibitor PF-00868554 administered as monotherapy in HCV genotype 1 infected subjects. Hepatology 2008;48:1024A-5A
   Web of Science ®Google Scholar
• Srinivasan S, Jagannatha S, Cui Y, et al. Safety and tolerability of filibuvir, a non nucleoside inhibitor of HCV polymerase. HepDART 2009. Koala coast, Hawaii, USA. Available from: www.natap.org/2009/hepDART/hepDART_05.htm [Last accessed 30 June 2014]
   Google Scholar
• Wagner F, Thompson R, Kantaridis C, et al. Antiviral activity of the hepatitis c virus polymerase inhibitor filibuvir in genotype 1 infected patients. Hepatology 2011;54:50-9
   PubMed Web of Science ®Google Scholar
• Troke PJ, Lewis M, Simpson P, et al. Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients. Antimicrob Agents Chemother 2012;56:1331-41
   PubMed Web of Science ®Google Scholar
• Jacobson I, Pockros P, Lalezari J, et al. Antiviral activity of filibuvir in combination with pegylated interferon alfa-2a and ribavirin for 28 days in treatment naive patients chronically infected with HCV genotype 1. J Hepatol 2009;50:S382-S83
   Web of Science ®Google Scholar
• Jacobson I, Pockros PJ, Lalezari J, et al. Virologic response rates following 4 weeks of filibuvir in combination with pegylated interferon alfa-2a and ribavirin in chronically-infected HCV genotype-1 patients. J Hepatol 2010;52:S465-S65
   Web of Science ®Google Scholar
• Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol 2011;54:1273-85
   PubMed Web of Science ®Google Scholar
• Schlaphoff V, Klade CS, Jilma B, et al. Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+T cells in healthy individuals and chronic hepatitis C patients. Vaccine 2007;25:6793-806
   PubMed Web of Science ®Google Scholar
• Firbas C, Jilma B, Tauber E, et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 2006;24:4343-53
   PubMed Web of Science ®Google Scholar
• Dietz J, Boehm T, Füller C, et al. 1203 clonal sequencing of HCV NS3 protease and helicase T cell epitopes in patients immunized with the therapeutic HCV vaccine IC41. J Hepatol 2011;54:S475
   Web of Science ®Google Scholar
• Wedemeyer H, Berg T, Manns MP, et al. Induction of TH1/TC1 type immunity in chronic hepatitis C non-responder patients with the therapeutic peptide vaccine IC41. J Hepatol 2005;42:9-10
   Web of Science ®Google Scholar
• Intercell AG. Favourable six months follow-up results from Intercell’s phase ii therapeutic hepatitis c program. 2008. Available from: www.hepatitiscentral.com/mt/archives/2008/09/hcv_genotype_1.html [Last accessed 30 June 2014]
   Google Scholar
• Fukumura A, Tsutsumi M, Tsuchishima M, et al. Effect of the inducer of interleukin-6 (ME3738) on rat liver treated with ethanol. Alcoholism-Clinical and Experimental Research 2007;31:49S-53S
   PubMed Web of Science ®Google Scholar
• Abe H, Imamura M, Hiraga N, et al. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo. J Hepatol 2011;55:11-18
   PubMed Web of Science ®Google Scholar
• Saibara T, Enomoto N, Kaneko S, et al. Clinical efficacy of combination therapy with ME3738 and pegylated interferon-alpha-2a in patients with hepatitis C virus genotype 1. Hepatol Res 2014;44:410-19
   PubMed Web of Science ®Google Scholar
• Vernachio JH, Bleiman B, Bryant KD, et al. INX-08189, a Phosphoramidate Prodrug of 6-O-Methyl-2 ’-C-Methyl Guanosine, Is a Potent Inhibitor of Hepatitis C Virus Replication with Excellent Pharmacokinetic and Pharmacodynamic Properties. Antimicrob Agents Chemother 2011;55:1843-51
   PubMed Web of Science ®Google Scholar
• Li W, Gao M, Hall A, et al. In vitro characterization of the combination of daclatasvir, an NS5A inhibitor, and BMS-986094 (INX-08189), a precursor to an NS5B inhibitor. Hepatology 2012;56:1074A-5A
   PubMed Web of Science ®Google Scholar
• Patti J, Matson M, Boehlecke B, et al. A study of the safety and pharmacokinetics of single ascending oral doses of INX-08189, a nucleotide polymerase inhibitor, in healthy subjects. J Hepatol 2011;54:S187-S87
   PubMed Web of Science ®Google Scholar
• Rodriguez-Torres M, Lawitz E, Hazan L, et al. Antiviral activity and safety of INX-08189, a nucleotide polymerase inhibitor, following 7-days of oral therapy in naive genotype-1 chronic HCV patients. Hepatology 2011;54:535A-A
   Web of Science ®Google Scholar
• Lawitz E, Lalezari J, Freilich B, et al. BMS-986094 (INX-08189) Plus Peginterferon Alfa-2a and Ribavirin Results in Increased Rates of Rapid Virologic Response (RVR) and eRVR in Treatment-Naive HCV-Genotype 2/3 Patients Compared to Peginterferon Alfa-2a and Ribavirin: week 12 Results. Hepatology 2012;56:566A-7A
   Web of Science ®Google Scholar
• Bristol - Myers Squibb Pharmaceuticals. Press release. 2012. Available from: http://cenblog.org/the-haystack/tag/bms/ [Last accessed 30 June 2014]
   Google Scholar
• Smith M. Safety issue halts study of BMS HCV drug. 2012. Available from: www.medpagetoday.com/InfectiousDisease/Hepatitis/34025 [Last accessed 09 August 2014]
   Google Scholar
• Zhou X-J, Pietropaolo K, Chen J et al.Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis c virus, in healthy subjects. Antimicrob Agents Chemother 2011;55:76-81
   PubMed Web of Science ®Google Scholar
• Lalezari J, Box T, O’Riordan W, et al. IDX184 in combination with pegylated interferon-alpha 2a and ribavirin for 2 weeks in treatment-naive patients with chronic hepatitis C. Antivir Ther 2013;18:755-64
   PubMed Web of Science ®Google Scholar
• McCarville JF, Li B, Gillum JM, et al. In vitro and in vivo resistance profile of IDX184, a novel nucleotide analog for the treatment of HCV infection. 5th International Workshop on Hepatitis C, Resistance and New Compounds; 24-25 June 2010; Boston, USA
   Google Scholar
• Idenix Pharmaceuticals. Idenix Pharmaceuticals provides update on IDX184 and IDX19368 development programs. 2013. Available from: http://ir.idenix.com/releasedetail.cfm?releaseid=737733 [Last accessed 02 July 2014]
   Google Scholar
• Feuerstein A. Hep C drug panic! pharmasset stumble ripples through sector. 2011. Available from: www.thestreet.com/_yahoo/story/11348343/1/hep-c-drug-panic-pharmasset-stumble-ripples-through-sector.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA [Last accessed 09 September 2014]
   Google Scholar
• Lam AM, Espiritu C, Bansal S, et al. Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA. J Virol 2011;85:12334-42
   PubMed Web of Science ®Google Scholar
• Guedj J, Pang PS, Denning J, et al. Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938. Antivir Ther 2014;19:211-20
   PubMed Web of Science ®Google Scholar
• Vertex Pharmaceuticals. Hepatitis C virus polymerase inhibitor VX-222 reduced viral levels over three days in phase 1b trial. 2010. Available from: http://investors.vrtx.com/releasedetail.cfm?ReleaseID=460352 [Last accessed 02 July 2014]
   Google Scholar
• Jiang M, Zhang EZ, Ardzinski A, et al. Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor. Antimicrob Agents Chemother 2014;58:5456-65
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Sulkowski MS, Gane EJ, et al. VX-222, Telaprevir and Ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C: results of the ZENITH Study Interferon-Free Regimen. Hepatology 2012;56:308A-A
   Web of Science ®Google Scholar
• Gane E, Di Bisceglie A, Sulkowski M, et al. editors. Vertex QUAD Therapy Yielded 83-93% SVR with 12 weeks duration of therapy: VX-222/telaprevir in combination with peginterferon-alfa-2a and ribavirin in treatment-naïve genotype 1 HCV patients treated for 12 weeks: ZENITH STUDY, SVR12 interim analysis. Asian Pacific Association for the Study of the Liver (APASL); Taipei, Taiwan: 2012
   Google Scholar
• SciClone Pharmaceuticals. Press release. December 15, 2010. Available from: http://investor.sciclone.com/releasedetail.cfm?ReleaseID=537245 [Last accessed 30 June 2014]
   Google Scholar
• Colca JR. Discontinued drugs in 2012: endocrine and metabolic. Expert Opin Investig Drugs 2013;22:1305-13
   PubMed Web of Science ®Google Scholar
• Williams R. Discontinued drugs in 2012: oncology drugs. Expert Opin Investig Drugs 2013;22:1627-44
   PubMed Web of Science ®Google Scholar